Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. - Wikidata - awgldk - TriplyDB

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q54721275

about

Mast cell homeostasis and the JAK-STAT pathway Targeting JAK2 in the therapy of myeloproliferative neoplasms ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway AKT is a therapeutic target in myeloproliferative neoplasms STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms The JAK2 exon 12 mutations: a comprehensive review.Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.The involvement of Galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia Nuclear JAK2: form and function in cancer.STAT signaling in the pathogenesis and treatment of myeloid malignancies.Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis.Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.Emerging drugs for the treatment of myelofibrosis.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Primary myelofibrosis and its targeted therapy.Targeted Treatment Options in Mastocytosis.Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.Novel Therapies for Myelofibrosis.

P2860

Q24632515-AF77392D-41C0-413D-B414-380642021B7F Q26860796-2030D9CA-8785-4317-9753-35E69BFBF5CD Q28119162-50FDFEF9-C1AC-4F3C-9E68-DC8E77147AC2 Q28547283-DB180BF0-AA99-452A-901F-A54CDFA9B4DB Q33623277-B0147C63-9036-40E6-93AD-3DE5D2C93C5C Q33648325-136AB23D-D1AF-499B-9A6D-A836D01B42CA Q33982315-F5221950-8EAA-46AD-A2DC-DDF29B3229E1 Q34192739-7462542C-BDC8-4587-879F-10C542093481 Q34378552-B19B6E4A-571D-436D-9ABA-409A12E051B6 Q34575726-00BE795B-465B-4C4B-AD54-20408C0450C0 Q35433259-F465682D-721C-4641-A510-470C4CC68C1A Q35727453-9EB6046B-BEDB-4997-95AC-CB83D6C2C007 Q36003480-DE208EA6-0EF3-44ED-9A68-FAA627E1A4F2 Q36062042-17472D6D-628D-407A-B8C2-3E2CA9AF3091 Q37910092-D0133DD3-A480-4207-BD44-91EF3F0E506F Q38140880-0B5BE4E6-B24F-467A-B855-E1A00D9E6C23 Q38143243-3344C712-F47B-4578-BB4E-462D5E290F3F Q38370943-6952A424-9DC9-42DC-B253-45EA56B5AF04 Q38543775-90BA299D-2DE6-4F8E-80A1-4B348595E065 Q38684435-592C804C-1155-492D-9E06-D9EB07B8811C Q38931426-54F87BB7-CEFB-4658-A6F9-8701EB3C9023 Q41061871-4AD70EA7-6C84-4762-99B0-8881D1E68738 Q42760638-4A267F8F-C059-4C28-ABB2-36E2F6A82B35 Q49834761-23568392-1358-4C71-A131-A7FB577EB7C4 Q52817185-0ECBB6D9-74F4-4AC6-A82B-E6AEE6375BA4

P2860

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q54721275

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

@en

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

@nl

type

label

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

@en

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

@nl

prefLabel

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

@en

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

@nl

P1433

Q54721275-77A43F6F-BE78-42F3-B448-B2AFF5D8CCCD

P1476

Q54721275-CFEAD915-1833-43E0-A286-8C986CDE3677

P2093

Q54721275-0D57C0FF-7898-4378-8ECE-B7A69F43D296

Q54721275-182A3330-4909-4B9B-82E0-8F5D96B3D033

Q54721275-1D5CCD2C-7F4E-47B5-B9E9-3BAA4253AF26

Q54721275-3BD07BD5-F8BD-4B0A-8EED-50DFF16B49C8

Q54721275-5900B896-5A7C-44CF-AC27-D9D939160DBE

Q54721275-5C2777E9-886A-435D-9A89-C26D2351FDF8

Q54721275-6350AF97-398F-4F32-881F-25031A971C3B

Q54721275-8AD1806D-C3CA-4B94-8D7A-CA39A616028F

Q54721275-95BB01CD-9E8F-4FCA-A6EA-EF2762572B01

Q54721275-C52B1D52-9AA9-4E2C-BCEB-31832F7706F9

P2860

Q54721275-516C91A2-763F-4887-8ABC-55F8FDBB8E1A

Q54721275-6676F286-4028-4E7A-8AB5-A873361462CE

Q54721275-BC35D77D-F378-4CBA-905D-35867AD28EA2

P304

Q54721275-CC22014E-9B78-4075-9754-DBD3F0896253

P31

Q54721275-6B5A623D-EF95-4026-8CBC-B1CCBD152D74

P356

Q54721275-4353680B-3C06-474B-AFE5-60A8D40426A4

P407

Q54721275-0F1B6D97-44CD-4A11-8722-8FDF62FBD365

P433

Q54721275-653B42AC-D6E5-4FEF-BE6A-A21F2D4B2606

P478

Q54721275-0B81BEA0-8FB1-4757-AD4E-BA4987277D47

P50

Q54721275-1E5F13C8-EABA-4821-8794-B3C27005D112

P577

Q54721275-4C3F5945-9DBF-47E2-86B9-A56211843495

P5875

Q54721275-81F2413F-4A02-43ED-8FED-8B124B696AC1

P698

Q54721275-0BE9B6D2-96D2-49FD-A52C-D748873D6B7A

P356

J.1365-2141.2009.07870.X

P1433

British Journal of Haematology

P1476

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms

@en

P2093

Amy Quinn

http://www.w3.org/2001/XMLSchema#string

Anthony J Bench

http://www.w3.org/2001/XMLSchema#string

Colin Tristram

http://www.w3.org/2001/XMLSchema#string

Elaine M Boyd

http://www.w3.org/2001/XMLSchema#string

Gary McIntosh

http://www.w3.org/2001/XMLSchema#string

Lisa Happerfield

http://www.w3.org/2001/XMLSchema#string

Lizz F Grimwade

http://www.w3.org/2001/XMLSchema#string

Marie Hall

http://www.w3.org/2001/XMLSchema#string

Mark Rees

http://www.w3.org/2001/XMLSchema#string

Mike A Scott

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.

Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.

P304

495-506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2009.07870.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

147

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26805601

http://www.w3.org/2001/XMLSchema#string

P698

19747364

http://www.w3.org/2001/XMLSchema#string